Prosecution Insights
Prosecution Insights
11 pending office actions • 9 art units • 10 examiners • 0 of 11 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 4 (36%) |
| §102 only | 1 (9%) |
| §112 only | 2 (18%) |
| Double-patenting + other | 1 (9%) |
| Multi-statute (no §101) | 2 (18%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 2 | 12.2% | +18.7% |
| PEDAPATI, CHANDHANA | 1 | 74.2% | +21.8% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| BAUSCH, SARAE L | 1 | 29.6% | +44.2% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +40.3% |
| WILSON, MICHAEL C | 1 | 41.4% | +17.5% |
| MOHAMMED, SHAHDEEP | 1 | 51.5% | +57.0% |
| BATES, KEENAN ALEXANDER | 1 | 44.8% | +76.5% |
| HOEKSTRA, JEFFREY GERBEN | 1 | 55.7% | +39.6% |
| SINGH, ANOOP KUMAR | 1 | 42.8% | +67.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035319 | MODIFIED ANTISENSE OLIGONUCLEOTIDES TARGETING SPLICING FACTORS | POHNERT, STEVEN C | 38d overdue |
| 17813561 | METHOD OF SELECTING A TREATMENT FOR AN MS PATIENT | HOEKSTRA, JEFFREY GERBEN | 72d |
| 18454192 | TARGETED DNA DEMETHYLATION AND METHYLATION | BRETZ, COREY LANE | — |
| 18001841 | Small Deletion Signatures | BAUSCH, SARAE L | — |
| 18272260 | PROGNOSTIC METHODS FOR PLATINUM-BASED CHEMOTHERAPEUTICS | POHNERT, STEVEN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18327976 | MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENT | NOBLE, MARCIA STEPHENS | 49d overdue |
| 18035319 | MODIFIED ANTISENSE OLIGONUCLEOTIDES TARGETING SPLICING FACTORS | POHNERT, STEVEN C | 38d overdue |
| 18560081 | Determining Visual Frailty Index Using Machine Learning Models | PEDAPATI, CHANDHANA | 30d overdue |
| 18007429 | Automated Phenotyping of Behavior | MOHAMMED, SHAHDEEP | 14d |
| 17813561 | METHOD OF SELECTING A TREATMENT FOR AN MS PATIENT | HOEKSTRA, JEFFREY GERBEN | 72d |
| 18001841 | Small Deletion Signatures | BAUSCH, SARAE L | — |
| 18272260 | PROGNOSTIC METHODS FOR PLATINUM-BASED CHEMOTHERAPEUTICS | POHNERT, STEVEN C | — |
| 18019999 | SINGLE GENERATION TARGETED GENE INTEGRATION | WILSON, MICHAEL C | — |
| Art Unit | Apps |
|---|---|
| 1683 | 2 |
| 1632 | 2 |
| 2669 | 1 |
| 1635 | 1 |
| 1699 | 1 |
| 1638 | 1 |
| 3797 | 1 |
| 1631 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560081 | Determining Visual Frailty Index Using Machine Learning Models | PEDAPATI, CHANDHANA | 2669 | §103 | Final Rejection | 30d overdue | Pending | Nov 09, 2023 |
| 18454192 | TARGETED DNA DEMETHYLATION AND METHYLATION | BRETZ, COREY LANE | 1635 | §103DPOther | Non-Final OA | — | Pending | Aug 23, 2023 |
| 18001841 | Small Deletion Signatures | BAUSCH, SARAE L | 1699 | §101§102§112 | Non-Final OA | — | Pending | Jul 24, 2023 |
| 18272260 | PROGNOSTIC METHODS FOR PLATINUM-BASED CHEMOTHERAPEUTICS | POHNERT, STEVEN C | 1683 | §103 | Non-Final OA | — | Pending | Jul 13, 2023 |
| 18327976 | MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENT | NOBLE, MARCIA STEPHENS | 1632 | §112 | Final Rejection | 49d overdue | Pending | Jun 02, 2023 |
| 18035319 | MODIFIED ANTISENSE OLIGONUCLEOTIDES TARGETING SPLICING FACTORS | POHNERT, STEVEN C | 1683 | §102§103 | Final Rejection | 38d overdue | Pending | May 04, 2023 |
| 18019999 | SINGLE GENERATION TARGETED GENE INTEGRATION | WILSON, MICHAEL C | 1638 | §103 | Non-Final OA | — | Pending | Feb 06, 2023 |
| 18007429 | Automated Phenotyping of Behavior | MOHAMMED, SHAHDEEP | 3797 | §102 | Non-Final OA | 14d | Pending | Jan 30, 2023 |
| 18015042 | TRANSGENIC MOUSE MODELS SUPPORTING HUMAN INNATE IMMUNE FUNCTION | BATES, KEENAN ALEXANDER | 1631 | §103 | Final Rejection | — | Pending | Jan 06, 2023 |
| 17813561 | METHOD OF SELECTING A TREATMENT FOR AN MS PATIENT | HOEKSTRA, JEFFREY GERBEN | 3791 | §102§112 | Final Rejection | 72d | Pending | Jul 19, 2022 |
| 17767311 | HIGH FREQUENCY TARGETED ANIMAL TRANSGENESIS | SINGH, ANOOP KUMAR | 1632 | §112Other | Non-Final OA | — | Pending | Apr 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial